Karyopharm establishes partnership with national cancer institute to advance xpovio (selinexor) research

Karyopharm establishes partnership with national cancer institute to advance xpovio® (selinexor) research.karyopharm therapeutics inc - crada will focus on advancing xpovio.karyopharm therapeutics - under terms, nci to collaborate with co on studies to investigate safety, efficacy of xpovio in various oncology indications.karyopharm therapeutics - nci may support studies to explore important future combinations of xpovio with targeted/standard of care cancer agents.
KPTI Ratings Summary
KPTI Quant Ranking